FLAIROF

This brand name is authorized in Nigeria.

Active ingredients

The drug FLAIROF contains one active pharmaceutical ingredient (API):

1	Roflumilast UNII 0P6C6ZOP5U - ROFLUMILAST
	Roflumilast is a PDE4 inhibitor, a non-steroid, anti-inflammatory active substance designed to target both the systemic and pulmonary inflammation associated with COPD.
	Read more about Roflumilast

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A4-100659	Tablet	FLAIROF TABLETS TAB 250 mcg 1 X 15	32 NF-PP-335462 FLAIROF TABLETS ROFLUMILAST 250MCG ROFLUMILAST 250MCG,MANNITOL,MICROCRYSTALLINE CELLULOSE,COLLOIDAL SILICON DI OXIDE,MAGNESIUM STEARATE A4-100659 Drugs Imported Products 1x15 Prescription Only Medicine (POM) 7/22/2023 HETERO LABS NIGERIA LIMITED, NO. 8B, WOLE OGUNJIMI STREET, AGBAOKU ESTATE, OFF OPEBI ROAD, IKEJA, LAGOS. 8060878739 heteronig@yahoo.com HETERO LABS LIMITED, UNIT 1, KALYANPUR VILLAGE, CHAKKAN ROAD, BADDI DIST, SOLAN (H.P) INDIA, Nigeria	21/12/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R03DX07	Roflumilast	R Respiratory system → R03 Drugs for obstructive airway diseases → R03D Other systemic drugs for obstructive airway diseases → R03DX Other systemic drugs for obstructive airway diseases
Discover more medicines within R03DX07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A4-100659